5612 Results

People

  1. Giralt
    Giralt
  2. Ladanyi
    Ladanyi
  3. Arcila
    Arcila
  4. Perales
    Perales
  5. Drilon
    Drilon
  6. Hyman
    Hyman
  7. Berger
    Berger
  8. Solit
    Solit
  9. Motzer
    Motzer
  10. Reis-Filho
    Reis-Filho

Groups

  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)
  7. Center for Hematologic Malignancies (914)
  8. Survivorship Research (910)
  9. Department of Pathology and Laboratory Medicine (784)
  10. Population Sciences Research Program (751)
  1. "2019"
Formats
  1. Journal Article (2145)
  2. Meeting Abstract (2088)
  3. Review (529)
  4. Editorial (275)
  5. Book Section (252)
  6. Guidelines (108)
  7. Correspondence (89)
  8. Research Letter (47)
  9. Conference Paper (44)
  10. Miscellaneous (25)
  11. Book Whole (10)
Groups
  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)

More Groups

People
  1. Sergio Giralt (97)
  2. Marc Ladanyi (96)
  3. Maria Arcila (84)
  4. Miguel-Angel Perales (82)
  5. Alexander Drilon (76)
  6. David Hyman (74)

More People

Years
  1. 2019 (5612)
Publications
  1. Journal of Clinical Oncology (457)
  2. Blood (268)
  3. Cancer Research (192)
  4. Annals of Oncology (163)
  5. International Journal of Radiation Oncology, Biology, Physics (124)
  6. Modern Pathology (112)

More Publications

Publishers
  1. Elsevier Inc. (696)
  2. American Society of Clinical Oncology (518)
  3. Springer (445)
  4. American Association for Cancer Research (343)
  5. Nature Publishing Group (337)
  6. Oxford University Press (325)

More Publishers

Results (5612)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic impact of chromosomal abnormalities and copy number alterations among adults with B-cell precursor acute lymphoblastic leukaemia treated on UKALL14
    Meeting Abstract

    Moorman, A. V.; Butler, E.; Barretta, E.; Kirkwood, A. A.; Schwab, C.; Creasey, T.; Leongamornlert, D. A.; Papaemmanuil, E.; Patrick, P.; Clifton-Hadley, L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase Ia/Ib study exploring the synthetic lethality of the orally administered novel BTK inhibitor, Dtrmwxhs-12 (DTRM-12), in combination with everolimus and pomalidomide in patients with relapsed/refractory CLL, DLBCL or other B-cell lymphomas
    Meeting Abstract

    Mato, A. R.; Schuster, S. J.; Foss, F. M.; Isufi, I.; Ding, W.; Brander, D. M.; Sitlinger, A.; Tun, H. W.; Moustafa, M. A.; Kennard, K.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Results from a first-in-human, proof-of-concept phase 1 trial in pretreated B-cell malignancies for loxo-305, a next-generation, highly selective, non-covalent BTK inhibitor
    Meeting Abstract

    Mato, A. R.; Flinn, I. W.; Pagel, J. M.; Brown, J. R.; Cheah, C. Y.; Coombs, C. C.; Patel, M. R.; Rothenberg, S. M.; Tsai, D. E.; Ku, N. C.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Efficacy of therapies following venetoclax discontinuation in CLL: Focus on B-cell receptor signal transduction inhibitors and cellular therapies
    Meeting Abstract

    Mato, A. R.; Roeker, L. E.; Eyre, T. A.; Jacobs, R.; Hill, B. T.; Lamanna, N.; Brander, D. M.; Shadman, M.; Ujjani, C.; Yazdy, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Combined treatment with lenalidomide and epoetin alfa leads to durable responses in patients with epo-refractory, lower risk non-deletion 5q [del(5q)] MDS: Final results of the E2905 intergroup phase III study - An ECOG-ACRIN Cancer Research Group study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health
    Meeting Abstract

    List, A. F.; Sun, Z.; Verma, A.; Bennett, J. M.; McGraw, K.; Maciejewski, J. P.; Komrokji, R. S.; Wassenaar, T. R.; Luger, S. M.; Mattison, R. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Expansion of prior existing TP53 mutated clones in polycythemia vera patients treated with idasanutlin
    Meeting Abstract

    Marcellino, B.; Cassinat, B.; Farnoud, N.; Lu, M.; Verger, E.; McGovern, E.; Patel, M. A.; Kosiorek, H. E.; Mehrotra, M.; Houldsworth, J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • TP53 action and the consequences of TP53 mutation in acute myeloid leukemia
    Meeting Abstract

    Lowe, S. W.
    Blood (2019)

    Fulltext@MSK | Save
  • Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: A first real-world look at patient characteristics, healthcare utilization and costs
    Meeting Abstract

    Kilgore, K. M.; Mohammadi, I.; Schroeder, A.; Teigland, C.; Purdum, A.; Shah, G. L.
    Blood (2019)

    Fulltext@MSK | Save
  • Complete response status according to RECIL 2017 criteria shows high concordance with Lugano 2014 criteria and is highly prognostic for outcome in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Kostakoglu, L.; Martelli, M.; Sehn, L. H.; Trněný, M.; Vitolo, U.; Knapp, A.; Mattiello, F.; Nielsen, T. G.; Sahin, D.; Sellam, G.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Clinical impact of ibrutinib with R-CHOP in untreated non-GCB DLBCL co-expressing BCL2 and MYC Genes in the phase 3 PHOENIX trial
    Meeting Abstract

    Johnson, P.; Balasubramanian, S.; Hodkinson, B.; Schaffer, M.; Parisi, L.; Shreeve, S. M.; Sun, S.; Vermeulen, J.; Sehn, L. H.; Staudt, L.; more...
    Blood (2019)

    Fulltext@MSK | Save